JP6684715B2 - リソソーム酵素のための基質クリアランスアッセイ - Google Patents
リソソーム酵素のための基質クリアランスアッセイ Download PDFInfo
- Publication number
- JP6684715B2 JP6684715B2 JP2016551191A JP2016551191A JP6684715B2 JP 6684715 B2 JP6684715 B2 JP 6684715B2 JP 2016551191 A JP2016551191 A JP 2016551191A JP 2016551191 A JP2016551191 A JP 2016551191A JP 6684715 B2 JP6684715 B2 JP 6684715B2
- Authority
- JP
- Japan
- Prior art keywords
- lysosomal enzyme
- cells
- potency
- lysosomal
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 200
- 108090000790 Enzymes Proteins 0.000 title claims description 200
- 230000002132 lysosomal effect Effects 0.000 title claims description 165
- 239000000758 substrate Substances 0.000 title claims description 86
- 238000003556 assay Methods 0.000 title description 60
- 210000004027 cell Anatomy 0.000 claims description 178
- 238000000034 method Methods 0.000 claims description 119
- 230000036515 potency Effects 0.000 claims description 88
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 27
- 102000005262 Sulfatase Human genes 0.000 claims description 15
- 108060007951 sulfatase Proteins 0.000 claims description 15
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 8
- 231100000673 dose–response relationship Toxicity 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims description 4
- 108010060309 Glucuronidase Proteins 0.000 claims description 4
- 102000053187 Glucuronidase Human genes 0.000 claims description 4
- 101710202061 N-acetyltransferase Proteins 0.000 claims description 4
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 108010023320 N-acetylglucosamine-6-sulfatase Proteins 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 2
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 49
- 229920002683 Glycosaminoglycan Polymers 0.000 description 45
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 description 18
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 description 18
- 238000012360 testing method Methods 0.000 description 12
- 230000004700 cellular uptake Effects 0.000 description 11
- 238000007405 data analysis Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 5
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002641 enzyme replacement therapy Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- -1 α-iduronidase Proteins 0.000 description 4
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000015100 lysosomal transport Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011165 process development Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 102100027165 Alpha-2-macroglobulin receptor-associated protein Human genes 0.000 description 2
- 101710126837 Alpha-2-macroglobulin receptor-associated protein Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101710190709 Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 102000056067 N-acetylglucosamine-6-sulfatases Human genes 0.000 description 2
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 2
- 102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 2
- 101710132062 Transitional endoplasmic reticulum ATPase Proteins 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000011072 cell harvest Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007331 pathological accumulation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000005072 1,3,4-oxadiazoles Chemical class 0.000 description 1
- QKLPIYTUUFFRLV-YTEMWHBBSA-N 1,4-bis[(e)-2-(2-methylphenyl)ethenyl]benzene Chemical compound CC1=CC=CC=C1\C=C\C(C=C1)=CC=C1\C=C\C1=CC=CC=C1C QKLPIYTUUFFRLV-YTEMWHBBSA-N 0.000 description 1
- XJKSTNDFUHDPQJ-UHFFFAOYSA-N 1,4-diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 XJKSTNDFUHDPQJ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CNRNYORZJGVOSY-UHFFFAOYSA-N 2,5-diphenyl-1,3-oxazole Chemical compound C=1N=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 CNRNYORZJGVOSY-UHFFFAOYSA-N 0.000 description 1
- FCNCGHJSNVOIKE-UHFFFAOYSA-N 9,10-diphenylanthracene Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 FCNCGHJSNVOIKE-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XZCJVWCMJYNSQO-UHFFFAOYSA-N butyl pbd Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=NN=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)O1 XZCJVWCMJYNSQO-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 229930184652 p-Terphenyl Natural products 0.000 description 1
- GPRIERYVMZVKTC-UHFFFAOYSA-N p-quaterphenyl Chemical group C1=CC=CC=C1C1=CC=C(C=2C=CC(=CC=2)C=2C=CC=CC=2)C=C1 GPRIERYVMZVKTC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7057—(Intracellular) signaling and trafficking pathways
- G01N2800/7066—Metabolic pathways
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461941365P | 2014-02-18 | 2014-02-18 | |
| US61/941,365 | 2014-02-18 | ||
| PCT/US2015/016394 WO2015126953A1 (en) | 2014-02-18 | 2015-02-18 | Substrate clearance assays for lysosomal enzymes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017506508A JP2017506508A (ja) | 2017-03-09 |
| JP6684715B2 true JP6684715B2 (ja) | 2020-04-22 |
Family
ID=52649105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551191A Active JP6684715B2 (ja) | 2014-02-18 | 2015-02-18 | リソソーム酵素のための基質クリアランスアッセイ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11187697B2 (enExample) |
| EP (1) | EP3108258B1 (enExample) |
| JP (1) | JP6684715B2 (enExample) |
| CN (1) | CN105980859B (enExample) |
| AU (1) | AU2015219097B2 (enExample) |
| BR (1) | BR112016018978B1 (enExample) |
| CA (1) | CA2938498A1 (enExample) |
| EA (1) | EA201691393A1 (enExample) |
| MX (1) | MX373640B (enExample) |
| WO (1) | WO2015126953A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11396499B2 (en) | 2018-12-12 | 2022-07-26 | University Of Washington | Lysosomal acid lipase assay |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0650396T3 (da) * | 1993-05-17 | 1998-09-14 | Amersham Int Plc | Udstyr og fremgangsmåde til måling af celluære biokemiske processer. |
| DK1007971T3 (da) * | 1997-08-18 | 2004-12-06 | Amersham Plc | Scintillationsproximitetstest |
| AR034413A1 (es) * | 2000-08-25 | 2004-02-25 | Nestor Abel Chamoles | Metodo para determinar la actividad de las enzimas lisosomales |
| US20050244907A1 (en) * | 2003-12-15 | 2005-11-03 | Applera Corporation | Methods, compositions, and kits for analysis of enzyme activity in cells |
| WO2009006877A2 (de) | 2007-07-06 | 2009-01-15 | Papst Licensing Gmbh & Co. Kg | Bestimmung der aktivität von proteasen |
| MX2010007846A (es) * | 2008-01-18 | 2010-10-05 | Biomarin Pharm Inc | Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas. |
| WO2011100392A2 (en) * | 2010-02-10 | 2011-08-18 | Nova Southeastern University | Methionine gamma lyase-2-aminobutyrate (megl-2abd) and therapeutic uses thereof |
-
2015
- 2015-02-18 JP JP2016551191A patent/JP6684715B2/ja active Active
- 2015-02-18 MX MX2016010719A patent/MX373640B/es active IP Right Grant
- 2015-02-18 AU AU2015219097A patent/AU2015219097B2/en active Active
- 2015-02-18 WO PCT/US2015/016394 patent/WO2015126953A1/en not_active Ceased
- 2015-02-18 EP EP15709389.9A patent/EP3108258B1/en active Active
- 2015-02-18 CA CA2938498A patent/CA2938498A1/en not_active Abandoned
- 2015-02-18 BR BR112016018978-7A patent/BR112016018978B1/pt active IP Right Grant
- 2015-02-18 US US15/119,324 patent/US11187697B2/en active Active
- 2015-02-18 EA EA201691393A patent/EA201691393A1/ru unknown
- 2015-02-18 CN CN201580008136.XA patent/CN105980859B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11187697B2 (en) | 2021-11-30 |
| EP3108258A1 (en) | 2016-12-28 |
| WO2015126953A1 (en) | 2015-08-27 |
| CN105980859A (zh) | 2016-09-28 |
| JP2017506508A (ja) | 2017-03-09 |
| MX2016010719A (es) | 2016-11-23 |
| BR112016018978A2 (enExample) | 2017-08-15 |
| EP3108258B1 (en) | 2019-12-04 |
| CN105980859B (zh) | 2018-10-19 |
| AU2015219097A1 (en) | 2016-08-18 |
| AU2015219097B2 (en) | 2021-02-11 |
| CA2938498A1 (en) | 2015-08-27 |
| MX373640B (es) | 2020-05-04 |
| EA201691393A1 (ru) | 2016-12-30 |
| US20170219566A1 (en) | 2017-08-03 |
| BR112016018978B1 (pt) | 2024-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sacchetto et al. | Modeling cardiovascular diseases with hiPSC-derived cardiomyocytes in 2D and 3D cultures | |
| Maloney et al. | Mesenchymal stem cell mechanics from the attached to the suspended state | |
| Kim et al. | A liver‐specific gene expression panel predicts the differentiation status of in vitro hepatocyte models | |
| Knorr et al. | YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes | |
| Tsvetkova et al. | γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation | |
| Kolanko et al. | The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery | |
| CN101400697B (zh) | 寻常鱼鳞病、特异反应性和其他病症的预防/治疗 | |
| Dubuisson et al. | Histological methods to assess skeletal muscle degeneration and regeneration in Duchenne muscular dystrophy | |
| Dai et al. | Microfluidic disc-on-a-chip device for mouse intervertebral disc—pitching a next-generation research platform to study disc degeneration | |
| Viganò et al. | Tips and tricks for validation of quality control analytical methods in good manufacturing practice mesenchymal stromal cell production | |
| Asnaghi et al. | Biomarker signatures of quality for engineering nasal chondrocyte-derived cartilage | |
| Gross et al. | Biomechanical modulation of dental pulp stem cell (DPSC) properties for soft tissue engineering | |
| JP6684715B2 (ja) | リソソーム酵素のための基質クリアランスアッセイ | |
| Sui et al. | TRIM72 restricts lyssavirus infection by inducing K48-linked ubiquitination and proteasome degradation of the matrix protein | |
| Bouchy et al. | Evolution of fluorescence polarization of 1, 6-diphenyl-1, 3, 5-hexatriene (DPH) during the labelling of living cells | |
| US20060003311A1 (en) | In vitro screening of cellular events using 3d cell culture systems | |
| Reihs et al. | An Animal‐Free Patient‐Derived Tissue‐Mimetic Biochip Model of the Human Synovial Membrane for Human‐Relevant Osteoarthritis Research | |
| US20020004043A1 (en) | Cellular and animal models for diseases associated with altered mitochondrial function | |
| Grossner et al. | 18F-based Quantification of the Osteogenic Potential of hMSCs | |
| Maldonado et al. | Protocol for measuring membrane elasticity of mouse cardiomyocytes using atomic force microscopy | |
| CN112813021A (zh) | 评估药物心血管安全性的细胞模型及方法 | |
| US20090305905A1 (en) | Compositions and methods relating to characterization and therapeutic application of pristine stem cells | |
| US20220017870A1 (en) | Methods of identifying therapeutic targets for treating angiogenesis | |
| Taejo et al. | Quality Control of Mesenchymal Stem Cells for Cell Therapies in Advanced Regenerative Medicine | |
| Le et al. | An optimized O9-1/hydrogel system for studying mechanical signals in neural crest cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180209 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190315 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200302 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200330 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6684715 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |